2. Academic Validation
  3. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia

Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia

  • Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26604. doi: 10.1002/pbc.26604.
Ichiko Kinjyo 1,  Ksenia Matlawska-Wasowska 2 3,  Xiaoru Chen 4,  Noel R Monks 5,  Patricia Burke 4,  Stuart S Winter 2 3,  Bridget S Wilson 1 2
Affiliations

Affiliations

  • 1 Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
  • 2 Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
  • 3 Division of Hematology/Oncology, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
  • 4 Translational Medicine Oncology, MedImmune, Gaithersburg, Maryland.
  • 5 Oncology Research, MedImmune, Gaithersburg, Maryland.
PMID: 28449314 DOI: 10.1002/pbc.26604
Abstract

Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and Apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rgnull mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models.

Keywords

acute lymphoblastic leukemia; immunotherapy.

Figures
Products